Literature DB >> 17639175

Endoscopic and ultrasonographic evaluation before and after Roux-en-Y gastric bypass for morbid obesity.

Marcelo Passos Teivelis1, Joel Faintuch, Robson Ishida, Paulo Sakai, Adriano Bresser, Joaquim Gama-Rodrigues.   

Abstract

BACKGROUND: Esophagogastric abnormalities are recognized prior and after bariatric procedures, but frequency and severity are debated. Liver and biliary tract findings are also of clinical importance, especially gallstones and liver steatosis. AIM: To compare pre-operative findings of hepatobiliary ultrasound and upper digestive endoscopy with post-operative results in patients submitted to open Roux-en-Y gastric bypass for morbid obesity.
METHODS: A total of 80 patients were enrolled 16.8 +/- 12.1 months after operation, all of them on routine follow-up program, and 8 were excluded. Retrospective analysis aimed at pre-operative clinical, endoscopic and ultrasonographic examinations and were prospectively repeated.
RESULTS: Pre-operative endoscopical report was available in 42 cases, and 52 examinations were performed post-operatively. Frequency of esophagitis changed from 16.7% (7/42) to 15.4% (8/52), and of gastritis from 45.2% (19/42) to 21.2% (11/52). Gastric or gastrojejunal ulcers were initially present in 4.8% (2/42) and increased to 9.6% (5/52). Post-operatively, an unusual abnormality was silastic band erosion: 7.7% (4/52). Helicobacter pylori was present in 50.0% (21/42) before and 3.5% (2/52) after operation. Ultrasonographic study had been done before intervention in 63 subjects, and 57 were executed on follow-up. Liver steatosis occurred previously in 58.7% (37/63) and in 43.9% (25/57) later on. Only 12.7% (8/63) of the patients had undergone cholecystectomy before bariatric operation, 29.1%(16/55) suffered simultaneous resection of gallbladder because of stones during Roux-en-Y gastric bypass, and an additional 26.8% (10/36) developed gallstones post-operatively.
CONCLUSIONS: Liver steatosis did not statistically improve, nor did inflammatory conditions of the upper digestive tube, despite reduction of H. pylori infections; gallbladder stones requiring intervention were common.

Entities:  

Mesh:

Year:  2007        PMID: 17639175     DOI: 10.1590/s0004-28032007000100003

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  6 in total

1.  Prevalence of Cholelithiasis and Choledocholithiasis in Morbidly Obese South Indian Patients and the Further Development of Biliary Calculus Disease After Sleeve Gastrectomy, Gastric Bypass and Mini Gastric Bypass.

Authors:  Tapas Mishra; Kona Kumari Lakshmi; Kiran Kumar Peddi
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

2.  Cholecystolithiasis after gastric bypass: a clinical, biochemical, and ultrasonographic 3-year follow-up study.

Authors:  Rachid Nagem; Alcino Lázaro-da-Silva
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

3.  Incidence and Risk Factors for Cholelithiasis After Bariatric Surgery.

Authors:  Hernán M Guzmán; Matías Sepúlveda; Nicolás Rosso; Andrés San Martin; Felipe Guzmán; Hernán C Guzmán
Journal:  Obes Surg       Date:  2019-07       Impact factor: 4.129

Review 4.  Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery.

Authors:  Marilia Carabotti; Chiara D'Ercole; Angelo Iossa; Enrico Corazziari; Gianfranco Silecchia; Carola Severi
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

5.  Pattern of liver function tests in morbidly obese Saudi patients undergoing bariatric surgery.

Authors:  Ahmad Al Akwaa; Ahmad El Zubier; Mohammed Al Shehri
Journal:  Saudi J Gastroenterol       Date:  2011 Jul-Aug       Impact factor: 2.485

6.  Is Routine Preoperative Esophagogastroduodenoscopy Prior to Bariatric Surgery Mandatory? Systematic Review and Meta-analysis of 10,685 Patients.

Authors:  Walid El Ansari; Ayman El-Menyar; Brijesh Sathian; Hassan Al-Thani; Mohammed Al-Kuwari; Abdulla Al-Ansari
Journal:  Obes Surg       Date:  2020-08       Impact factor: 4.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.